| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
1.08(B) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,299 |
| 52
Week Range: |
$1.78 - $6.34 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nornhold Jeffrey |
SVP, Technical Operations |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,835) |
0 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(54,043) |
0 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• – – |
2018-03-02 |
4 |
D |
$19.50 |
$63,824 |
D/D |
(3,273) |
89,246 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• – – |
2018-03-02 |
4 |
D |
$19.50 |
$47,502 |
D/D |
(2,436) |
79,582 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• – – |
2018-03-02 |
4 |
D |
$19.50 |
$59,846 |
D/D |
(3,069) |
94,684 |
|
- |
|
| Boothe Douglas |
President, Generics Division |
• – – |
2018-03-02 |
4 |
D |
$19.50 |
$39,800 |
D/D |
(2,041) |
78,549 |
|
- |
|
| Nestor Michael |
President, Impax Specialty |
• – – |
2018-02-26 |
4 |
D |
$20.95 |
$116,210 |
D/D |
(5,547) |
101,396 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• – – |
2018-02-26 |
4 |
D |
$20.95 |
$124,380 |
D/D |
(5,937) |
92,519 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• – – |
2018-02-26 |
4 |
D |
$20.95 |
$128,654 |
D/D |
(6,141) |
97,753 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• – – |
2018-02-26 |
4 |
D |
$20.95 |
$88,304 |
D/D |
(4,215) |
82,018 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• – – |
2017-10-25 |
4 |
D |
$19.60 |
$53,586 |
D/D |
(2,734) |
86,233 |
|
- |
|
| Boothe Douglas |
President, Generics Division |
• – – |
2017-08-01 |
4 |
D |
$17.85 |
$94,284 |
D/D |
(5,282) |
80,590 |
|
- |
|
| Nestor Michael |
President, Impax Specialty |
• – – |
2017-05-31 |
4 |
S |
$15.00 |
$16,950 |
D/D |
(1,130) |
106,943 |
|
- |
|
| Nestor Michael |
President, Impax Specialty |
• – – |
2017-05-17 |
4 |
S |
$16.48 |
$14,119 |
D/D |
(857) |
108,073 |
|
- |
|
| Terreri Peter R |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
48,537 |
|
- |
|
| Benet Leslie Z |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
22,483 |
|
- |
|
| Buchi J Kevin |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,281 |
11,301 |
|
- |
|
| Bierly Rick |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
9,270 |
|
- |
|
| Pendergast Mary K |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
22,350 |
|
- |
|
| Burr Robert L |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
60,475 |
|
- |
|
| Vergis Janet S. |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
12,150 |
|
- |
|
| Chao Allen |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
69,445 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• – – |
2017-05-15 |
4 |
D |
$16.80 |
$7,627 |
D/D |
(454) |
103,894 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• – – |
2017-05-15 |
4 |
D |
$16.80 |
$58,598 |
D/D |
(3,488) |
98,456 |
|
- |
|
| Nestor Michael |
President, Impax Specialty |
• – – |
2017-05-15 |
4 |
D |
$16.80 |
$54,365 |
D/D |
(3,236) |
108,930 |
|
- |
|
215 Records found
|
|
Page 2 of 9 |
|
|
0.55 (8.86%) 
